Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of EBITDA Margin data on record, last reported at 314.93% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 33588.0% year-over-year to 314.93%; the TTM value through Dec 2025 reached 55.32%, up 2842.0%, while the annual FY2025 figure was 218.24%, 24514.0% down from the prior year.
  • EBITDA Margin reached 314.93% in Q4 2025 per COLL's latest filing, down from 285.23% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 41.2% in Q4 2023 and bottomed at 314.93% in Q4 2025.
  • Average EBITDA Margin over 5 years is 19.14%, with a median of 18.31% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: surged 13378bps in 2022, then tumbled -33588bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 124.71% in 2021, then skyrocketed by 107bps to 9.07% in 2022, then soared by 354bps to 41.2% in 2023, then crashed by -49bps to 20.95% in 2024, then crashed by -1604bps to 314.93% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 314.93% in Q4 2025, 285.23% in Q3 2025, and 18.67% in Q2 2025.